HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.

Abstract
The antithrombotic efficacy of lepirudin in patients with heparin-induced thrombocytopenia (HIT) is compromised by an increased risk for bleeding. A retrospective observational analysis in 181 patients (median age, 67 years) with confirmed HIT treated in routine practice with lepirudin was performed to identify predictive factors for thrombotic and bleeding complications. Lepirudin was administered at a mean (+/- SD) dose of 0.06 +/- 0.04 mg/kg/h (compared with a recommended initial dose of 0.15 mg/kg/h). Mean activated partial thromboplastin time was greater than 1.5 times baseline value in 99.4% of patients. Median treatment duration was 7.7 days. Until discharge from the hospital, 13.8% and 20.4% of patients experienced a thrombotic or a major bleeding event, respectively. On multivariate analysis, mean lepirudin dose was not a significant predictive factor for thrombosis. In contrast, mean lepirudin dose greater than 0.07 mg/kg/h, long duration of lepirudin treatment, and moderate to severe renal impairment were significant positive factors for major bleeding. Overall, these results suggest that the recommended dose of lepirudin in patients with HIT is too high; the use of reduced doses may be safer with regard to bleeding risk and does not compromise antithrombotic efficacy.
AuthorsBernard Tardy, Thomas Lecompte, Françoise Boelhen, Brigitte Tardy-Poncet, Ismaïl Elalamy, Pierre Morange, Yves Gruel, Martine Wolf, Dominique François, Evelyne Racadot, Philippe Camarasa, Marie Thérèse Blouch, Françoise Nguyen, Sylvie Doubine, Fabienne Dutrillaux, Martine Alhenc-Gelas, Isabelle Martin-Toutain, Anne Bauters, Patrick Ffrench, Emmanuel de Maistre, Lélia Grunebaum, Christine Mouton, Marie G Huisse, Michèle Gouault-Heilmann, Veronique Lucke, GEHT-HIT Study Group
JournalBlood (Blood) Vol. 108 Issue 5 Pg. 1492-6 (Sep 01 2006) ISSN: 0006-4971 [Print] United States
PMID16690967 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Hirudins
  • Recombinant Proteins
  • Heparin
  • lepirudin
Topics
  • Adolescent
  • Adult
  • Aged
  • Female
  • Hemorrhage
  • Heparin (adverse effects)
  • Hirudins
  • Humans
  • Male
  • Middle Aged
  • Recombinant Proteins (therapeutic use)
  • Retrospective Studies
  • Thrombocytopenia (chemically induced, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: